Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levodopa + carbidopa
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral, Intestinal
01
Overview
Levodopa + carbidopa is a fixed-dose combination of two small molecule drugs used primarily to treat the symptoms of Parkinson's disease and parkinsonism caused by other conditions such as encephalitis or poisoning. Levodopa acts as a prodrug that crosses the blood-brain barrier and is converted into dopamine, supplementing deficient dopamine levels in patients with Parkinson's disease. Carbidopa is a dopa decarboxylase inhibitor that prevents peripheral breakdown of levodopa, increasing its availability to the brain and reducing side effects like nausea. This combination does not slow or reverse disease progression but effectively manages motor symptoms such as tremor, rigidity, and bradykinesia[1][2][4][5].
- Brand names
- SinemetRytaryCrexontSinemet CRDuopaAtametCarbilev
- Other names
- carbidopa/levodopa
02
Targets
DDC (Aromatic L-amino acid decarboxylase)
Beyond the preview
Go deeper on levodopa + carbidopa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levodopa + carbidopa.